Unexpected reaction of “wild-type” gastrointestinal stromal tumor to imatinib: case report and literature review

ConclusionThis unexpected response suggests that wild-type GISTs may benefit from TKIs treatment, and the potential mechanisms warrant further investigation. Additionally, true wild-type GIST may not be discerned due to current limitations of Next-Generation Sequencing(NGS). Therefore, for advanced/high-risk GIST, additional genetic analysis can be performed after negative NGS results.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research